 Paco Herson
Concepts (480)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Ischemia | 34 | 2023 | 310 | 10.720 |
Why?
| | Heart Arrest | 23 | 2021 | 291 | 5.860 |
Why?
| | TRPM Cation Channels | 11 | 2021 | 68 | 5.040 |
Why?
| | Hippocampus | 21 | 2023 | 735 | 3.680 |
Why?
| | Neurons | 31 | 2023 | 1345 | 3.610 |
Why?
| | Stroke | 20 | 2023 | 1047 | 3.580 |
Why?
| | Neuroprotective Agents | 16 | 2020 | 111 | 3.460 |
Why?
| | Cardiopulmonary Resuscitation | 15 | 2021 | 225 | 3.090 |
Why?
| | Sex Characteristics | 14 | 2023 | 671 | 2.590 |
Why?
| | Cell Death | 16 | 2021 | 339 | 2.330 |
Why?
| | Purkinje Cells | 7 | 2019 | 65 | 2.290 |
Why?
| | Mice, Inbred C57BL | 45 | 2021 | 4908 | 1.790 |
Why?
| | Recovery of Function | 5 | 2021 | 604 | 1.780 |
Why?
| | CA1 Region, Hippocampal | 6 | 2019 | 30 | 1.580 |
Why?
| | Animals | 93 | 2023 | 33381 | 1.520 |
Why?
| | Androgens | 8 | 2014 | 167 | 1.510 |
Why?
| | Mice | 61 | 2023 | 15520 | 1.480 |
Why?
| | Long-Term Potentiation | 7 | 2019 | 148 | 1.360 |
Why?
| | Ischemia | 5 | 2022 | 374 | 1.330 |
Why?
| | Gonadal Steroid Hormones | 4 | 2018 | 122 | 1.300 |
Why?
| | Disease Models, Animal | 24 | 2022 | 3730 | 1.300 |
Why?
| | Neuroprotection | 3 | 2020 | 31 | 1.300 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 6 | 2023 | 159 | 1.220 |
Why?
| | Peptide Fragments | 2 | 2021 | 702 | 1.130 |
Why?
| | Receptors, GABA-A | 4 | 2021 | 89 | 1.080 |
Why?
| | Infarction, Middle Cerebral Artery | 12 | 2023 | 41 | 1.070 |
Why?
| | Poly(ADP-ribose) Polymerases | 4 | 2013 | 87 | 1.040 |
Why?
| | Reperfusion Injury | 8 | 2020 | 276 | 1.010 |
Why?
| | Hypothermia, Induced | 3 | 2016 | 68 | 1.010 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 4 | 2014 | 8 | 0.940 |
Why?
| | Male | 66 | 2023 | 57801 | 0.930 |
Why?
| | Calcium | 10 | 2022 | 1169 | 0.910 |
Why?
| | Brain Injuries, Traumatic | 4 | 2023 | 318 | 0.900 |
Why?
| | Thrombosis | 3 | 2022 | 309 | 0.850 |
Why?
| | Brain Injuries | 5 | 2021 | 484 | 0.840 |
Why?
| | Patch-Clamp Techniques | 13 | 2019 | 247 | 0.810 |
Why?
| | Cognition | 3 | 2019 | 1024 | 0.800 |
Why?
| | Neuronal Plasticity | 8 | 2023 | 219 | 0.780 |
Why?
| | Excitatory Postsynaptic Potentials | 3 | 2016 | 105 | 0.760 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 4 | 2020 | 191 | 0.750 |
Why?
| | Signal Transduction | 10 | 2021 | 4709 | 0.750 |
Why?
| | Brain | 12 | 2022 | 2490 | 0.750 |
Why?
| | Pregnanolone | 2 | 2011 | 21 | 0.730 |
Why?
| | Cerebellum | 4 | 2011 | 203 | 0.730 |
Why?
| | Estradiol | 5 | 2018 | 476 | 0.710 |
Why?
| | Brain-Derived Neurotrophic Factor | 4 | 2019 | 117 | 0.710 |
Why?
| | Sex Factors | 9 | 2018 | 1781 | 0.710 |
Why?
| | Nogo Proteins | 1 | 2019 | 10 | 0.690 |
Why?
| | Potassium Channels | 7 | 2003 | 123 | 0.660 |
Why?
| | Adult Stem Cells | 1 | 2018 | 35 | 0.630 |
Why?
| | Cognitive Dysfunction | 2 | 2019 | 301 | 0.630 |
Why?
| | Nerve Regeneration | 1 | 2018 | 53 | 0.630 |
Why?
| | Guideline Adherence | 1 | 2022 | 523 | 0.600 |
Why?
| | Long-Term Synaptic Depression | 2 | 2018 | 51 | 0.600 |
Why?
| | Estrogens | 5 | 2013 | 328 | 0.590 |
Why?
| | Neurogenesis | 1 | 2018 | 105 | 0.590 |
Why?
| | Mice, Knockout | 11 | 2021 | 2680 | 0.580 |
Why?
| | Neural Stem Cells | 1 | 2018 | 120 | 0.580 |
Why?
| | Nervous System Diseases | 1 | 2019 | 261 | 0.580 |
Why?
| | Aging | 3 | 2019 | 1670 | 0.570 |
Why?
| | Clotrimazole | 2 | 2013 | 2 | 0.560 |
Why?
| | Female | 40 | 2023 | 61565 | 0.560 |
Why?
| | Sirtuin 2 | 1 | 2015 | 13 | 0.550 |
Why?
| | Microglia | 5 | 2018 | 221 | 0.550 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 446 | 0.540 |
Why?
| | Oxygen | 4 | 2012 | 854 | 0.520 |
Why?
| | Cell Culture Techniques | 3 | 2013 | 356 | 0.500 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2018 | 407 | 0.500 |
Why?
| | Cell Hypoxia | 4 | 2013 | 220 | 0.500 |
Why?
| | Emergency Medical Services | 1 | 2022 | 589 | 0.490 |
Why?
| | Tissue Plasminogen Activator | 3 | 2022 | 231 | 0.490 |
Why?
| | Naltrexone | 1 | 2015 | 80 | 0.490 |
Why?
| | Animal Experimentation | 1 | 2014 | 6 | 0.490 |
Why?
| | Inhibitory Postsynaptic Potentials | 2 | 2011 | 32 | 0.480 |
Why?
| | Models, Animal | 2 | 2013 | 363 | 0.470 |
Why?
| | Rats | 18 | 2023 | 5392 | 0.460 |
Why?
| | Cerebral Cortex | 3 | 2021 | 416 | 0.450 |
Why?
| | Potassium Channels, Voltage-Gated | 2 | 2003 | 50 | 0.440 |
Why?
| | Peptides | 3 | 2023 | 879 | 0.430 |
Why?
| | Ion Channels | 4 | 2004 | 126 | 0.430 |
Why?
| | Neural Inhibition | 2 | 2011 | 160 | 0.420 |
Why?
| | Magnetic Fields | 3 | 2022 | 23 | 0.400 |
Why?
| | Synapses | 4 | 2021 | 344 | 0.390 |
Why?
| | Calcium Channels, T-Type | 2 | 2022 | 16 | 0.380 |
Why?
| | Hydrogen Peroxide | 4 | 2020 | 305 | 0.370 |
Why?
| | Memory | 3 | 2023 | 230 | 0.370 |
Why?
| | Oxidative Stress | 7 | 2020 | 1178 | 0.370 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 3 | 2014 | 29 | 0.360 |
Why?
| | Progesterone | 3 | 2010 | 242 | 0.360 |
Why?
| | Dexmedetomidine | 3 | 2014 | 52 | 0.350 |
Why?
| | Age Factors | 5 | 2021 | 2995 | 0.350 |
Why?
| | Drug Delivery Systems | 2 | 2022 | 306 | 0.340 |
Why?
| | Rats, Sprague-Dawley | 9 | 2023 | 2478 | 0.330 |
Why?
| | Immunohistochemistry | 7 | 2016 | 1691 | 0.330 |
Why?
| | Ion Channel Gating | 6 | 2004 | 85 | 0.330 |
Why?
| | Cerebrovascular Disorders | 1 | 2009 | 86 | 0.330 |
Why?
| | Glucose | 7 | 2014 | 953 | 0.330 |
Why?
| | Cells, Cultured | 10 | 2018 | 4077 | 0.320 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2014 | 984 | 0.320 |
Why?
| | Action Potentials | 6 | 2022 | 420 | 0.320 |
Why?
| | Sepsis | 3 | 2019 | 531 | 0.320 |
Why?
| | NAD | 2 | 1999 | 67 | 0.310 |
Why?
| | HEK293 Cells | 3 | 2020 | 625 | 0.310 |
Why?
| | Memory Disorders | 2 | 2019 | 168 | 0.300 |
Why?
| | Humans | 32 | 2023 | 118974 | 0.290 |
Why?
| | Brain Infarction | 3 | 2016 | 23 | 0.290 |
Why?
| | Colloids | 2 | 2017 | 60 | 0.280 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2019 | 1945 | 0.280 |
Why?
| | Dihydrotestosterone | 5 | 2013 | 39 | 0.270 |
Why?
| | Protective Agents | 2 | 2019 | 42 | 0.270 |
Why?
| | Time Factors | 11 | 2017 | 6412 | 0.260 |
Why?
| | Paraplegia | 2 | 2015 | 60 | 0.240 |
Why?
| | Military Personnel | 2 | 2023 | 529 | 0.240 |
Why?
| | Myelin Proteins | 3 | 2016 | 45 | 0.240 |
Why?
| | Epoxide Hydrolases | 2 | 2013 | 9 | 0.240 |
Why?
| | Receptors, Adrenergic, alpha-2 | 2 | 2013 | 17 | 0.230 |
Why?
| | Calmodulin | 2 | 2019 | 73 | 0.230 |
Why?
| | Oxidants | 2 | 2020 | 122 | 0.230 |
Why?
| | Olfactory Receptor Neurons | 1 | 2004 | 67 | 0.230 |
Why?
| | Spinocerebellar Degenerations | 1 | 2003 | 5 | 0.230 |
Why?
| | Glycosaminoglycans | 1 | 2023 | 78 | 0.230 |
Why?
| | Corpus Striatum | 4 | 2016 | 127 | 0.230 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 2 | 2013 | 40 | 0.230 |
Why?
| | Smell | 1 | 2004 | 118 | 0.230 |
Why?
| | Aspartic Acid Endopeptidases | 1 | 2023 | 22 | 0.230 |
Why?
| | Blood-Brain Barrier | 2 | 2022 | 108 | 0.230 |
Why?
| | Orchiectomy | 3 | 2013 | 57 | 0.230 |
Why?
| | Pneumonia | 2 | 2021 | 592 | 0.230 |
Why?
| | Amyloid beta-Protein Precursor | 1 | 2023 | 55 | 0.220 |
Why?
| | Behavior, Animal | 3 | 2018 | 486 | 0.220 |
Why?
| | Spinal Cord Ischemia | 2 | 2013 | 78 | 0.220 |
Why?
| | Spinal Cord | 3 | 2014 | 367 | 0.220 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2023 | 76 | 0.220 |
Why?
| | Heparitin Sulfate | 2 | 2019 | 42 | 0.220 |
Why?
| | Primary Cell Culture | 2 | 2013 | 155 | 0.210 |
Why?
| | Cerebral Infarction | 1 | 2022 | 45 | 0.210 |
Why?
| | Myelin Sheath | 3 | 2023 | 148 | 0.210 |
Why?
| | Emergency Medical Dispatch | 1 | 2022 | 7 | 0.210 |
Why?
| | Benzimidazoles | 2 | 2014 | 140 | 0.210 |
Why?
| | Spinal Cord Injuries | 2 | 2015 | 184 | 0.210 |
Why?
| | Phosphorylation | 4 | 2023 | 1633 | 0.210 |
Why?
| | Plasminogen | 1 | 2021 | 34 | 0.210 |
Why?
| | Receptors, Androgen | 3 | 2013 | 134 | 0.210 |
Why?
| | Information Systems | 1 | 2022 | 66 | 0.210 |
Why?
| | Heroin | 1 | 2021 | 19 | 0.200 |
Why?
| | Presynaptic Terminals | 1 | 2021 | 58 | 0.200 |
Why?
| | Organ Culture Techniques | 1 | 2021 | 149 | 0.200 |
Why?
| | gamma-Aminobutyric Acid | 2 | 2017 | 155 | 0.200 |
Why?
| | Cell Survival | 6 | 2020 | 1047 | 0.200 |
Why?
| | Islets of Langerhans | 2 | 1997 | 739 | 0.200 |
Why?
| | Eclampsia | 1 | 2020 | 5 | 0.200 |
Why?
| | Encephalitis | 2 | 2014 | 129 | 0.200 |
Why?
| | Blotting, Western | 5 | 2012 | 1194 | 0.200 |
Why?
| | Insulinoma | 2 | 1997 | 29 | 0.190 |
Why?
| | Thalamus | 1 | 2021 | 80 | 0.190 |
Why?
| | Cell-Derived Microparticles | 1 | 2021 | 62 | 0.190 |
Why?
| | Extinction, Psychological | 1 | 2021 | 81 | 0.190 |
Why?
| | Amyloid beta-Peptides | 1 | 2023 | 200 | 0.190 |
Why?
| | Insulin | 3 | 1999 | 2162 | 0.190 |
Why?
| | Extracellular Vesicles | 1 | 2021 | 76 | 0.190 |
Why?
| | Adaptation, Physiological | 1 | 2004 | 502 | 0.190 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2020 | 39 | 0.180 |
Why?
| | Death-Associated Protein Kinases | 1 | 2020 | 10 | 0.180 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 21 | 0.180 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 65 | 0.180 |
Why?
| | Fibrinolysis | 2 | 2021 | 159 | 0.180 |
Why?
| | Inhibitory Concentration 50 | 1 | 2019 | 81 | 0.180 |
Why?
| | Cell Membrane | 2 | 2003 | 710 | 0.180 |
Why?
| | Intravital Microscopy | 1 | 2019 | 25 | 0.180 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 982 | 0.180 |
Why?
| | Fibrinolytic Agents | 1 | 2022 | 238 | 0.180 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2019 | 65 | 0.180 |
Why?
| | Potassium Channels, Calcium-Activated | 3 | 2004 | 9 | 0.170 |
Why?
| | Optical Imaging | 1 | 2019 | 56 | 0.170 |
Why?
| | Axons | 2 | 2018 | 185 | 0.170 |
Why?
| | Mutagenesis | 1 | 2019 | 176 | 0.170 |
Why?
| | Oligosaccharides | 1 | 2019 | 54 | 0.170 |
Why?
| | Cofilin 1 | 1 | 2018 | 5 | 0.170 |
Why?
| | Models, Theoretical | 1 | 2023 | 556 | 0.170 |
Why?
| | Protein Aggregation, Pathological | 1 | 2018 | 17 | 0.170 |
Why?
| | Drug Design | 1 | 2019 | 160 | 0.170 |
Why?
| | Calcineurin | 1 | 2019 | 95 | 0.170 |
Why?
| | Nerve Net | 1 | 2021 | 232 | 0.170 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 522 | 0.160 |
Why?
| | Thalamic Nuclei | 1 | 2018 | 8 | 0.160 |
Why?
| | Holoenzymes | 1 | 2018 | 21 | 0.160 |
Why?
| | Mice, Transgenic | 5 | 2016 | 2025 | 0.160 |
Why?
| | Pre-Eclampsia | 1 | 2020 | 183 | 0.160 |
Why?
| | Lateral Ventricles | 1 | 2018 | 22 | 0.160 |
Why?
| | Interleukin-10 | 3 | 2015 | 306 | 0.160 |
Why?
| | Mitochondria | 2 | 2021 | 786 | 0.160 |
Why?
| | Molecular Dynamics Simulation | 1 | 2019 | 213 | 0.160 |
Why?
| | Myelin Proteolipid Protein | 1 | 2018 | 61 | 0.160 |
Why?
| | Membrane Proteins | 2 | 2021 | 1055 | 0.160 |
Why?
| | Heparin | 1 | 2019 | 230 | 0.160 |
Why?
| | Dementia | 1 | 2020 | 208 | 0.150 |
Why?
| | Intracranial Arterial Diseases | 1 | 2017 | 6 | 0.150 |
Why?
| | Alloxan | 1 | 1997 | 4 | 0.150 |
Why?
| | Receptors, AMPA | 2 | 2018 | 125 | 0.150 |
Why?
| | Glutathione | 1 | 1999 | 324 | 0.150 |
Why?
| | Receptors, Glutamate | 1 | 2016 | 20 | 0.150 |
Why?
| | Cerebral Arteries | 1 | 2017 | 56 | 0.150 |
Why?
| | Gene Knockdown Techniques | 2 | 2020 | 311 | 0.140 |
Why?
| | Pericytes | 1 | 2016 | 24 | 0.140 |
Why?
| | Inflammation | 4 | 2021 | 2566 | 0.140 |
Why?
| | Actins | 1 | 2018 | 404 | 0.140 |
Why?
| | Cations | 3 | 2003 | 79 | 0.140 |
Why?
| | Brain Concussion | 1 | 2023 | 470 | 0.140 |
Why?
| | Spleen | 3 | 2015 | 510 | 0.140 |
Why?
| | Leukoencephalopathies | 1 | 2016 | 32 | 0.140 |
Why?
| | Cell Communication | 2 | 2016 | 281 | 0.140 |
Why?
| | Collagen Type I | 1 | 2016 | 114 | 0.140 |
Why?
| | Furans | 1 | 2015 | 23 | 0.140 |
Why?
| | Tretinoin | 1 | 2016 | 116 | 0.130 |
Why?
| | Magnetic Resonance Angiography | 1 | 2017 | 210 | 0.130 |
Why?
| | Transfection | 2 | 2016 | 888 | 0.130 |
Why?
| | Arginase | 1 | 2015 | 29 | 0.130 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2013 | 333 | 0.130 |
Why?
| | Membrane Potentials | 5 | 1999 | 253 | 0.130 |
Why?
| | Calbindins | 1 | 2014 | 6 | 0.130 |
Why?
| | Mutation | 2 | 2020 | 3457 | 0.130 |
Why?
| | Dizocilpine Maleate | 1 | 2014 | 16 | 0.130 |
Why?
| | Interleukin-1beta | 2 | 2014 | 379 | 0.130 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 37 | 0.130 |
Why?
| | Calcium Channel Agonists | 1 | 2014 | 10 | 0.130 |
Why?
| | Quinolines | 1 | 2015 | 128 | 0.130 |
Why?
| | Neutrophil Activation | 1 | 2015 | 100 | 0.130 |
Why?
| | Trauma, Nervous System | 1 | 2014 | 3 | 0.130 |
Why?
| | Tissue Culture Techniques | 1 | 2014 | 67 | 0.130 |
Why?
| | Excitatory Amino Acid Antagonists | 1 | 2014 | 90 | 0.120 |
Why?
| | Microinjections | 2 | 2011 | 83 | 0.120 |
Why?
| | Electroencephalography | 1 | 2016 | 387 | 0.120 |
Why?
| | Lentivirus | 2 | 2011 | 52 | 0.120 |
Why?
| | Nerve Tissue Proteins | 2 | 2016 | 551 | 0.120 |
Why?
| | Cross Infection | 1 | 2016 | 205 | 0.120 |
Why?
| | Aortic Diseases | 1 | 2015 | 94 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2022 | 1440 | 0.120 |
Why?
| | Toll-Like Receptor 4 | 2 | 2013 | 330 | 0.120 |
Why?
| | CD40 Antigens | 1 | 2014 | 80 | 0.120 |
Why?
| | Analysis of Variance | 3 | 2015 | 1293 | 0.120 |
Why?
| | Arachidonic Acids | 1 | 2013 | 57 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2014 | 278 | 0.120 |
Why?
| | Body Temperature | 1 | 2014 | 215 | 0.120 |
Why?
| | Piperidines | 1 | 2014 | 171 | 0.110 |
Why?
| | bcl-2-Associated X Protein | 1 | 2013 | 46 | 0.110 |
Why?
| | Immune Tolerance | 1 | 2015 | 334 | 0.110 |
Why?
| | Embryo, Mammalian | 1 | 2013 | 220 | 0.110 |
Why?
| | Glomerular Filtration Barrier | 1 | 2012 | 1 | 0.110 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2013 | 198 | 0.110 |
Why?
| | Polymerase Chain Reaction | 3 | 2012 | 1012 | 0.110 |
Why?
| | Testosterone | 3 | 2010 | 351 | 0.110 |
Why?
| | RNA, Small Interfering | 2 | 2011 | 564 | 0.100 |
Why?
| | Endothelium | 1 | 2012 | 120 | 0.100 |
Why?
| | Microscopy, Immunoelectron | 1 | 2011 | 45 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2022 | 9342 | 0.100 |
Why?
| | Retrospective Studies | 7 | 2023 | 12978 | 0.100 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2011 | 50 | 0.100 |
Why?
| | Pyramidal Cells | 1 | 2011 | 54 | 0.100 |
Why?
| | United States | 3 | 2023 | 12555 | 0.100 |
Why?
| | Culture Media | 1 | 2011 | 163 | 0.100 |
Why?
| | Iraq War, 2003-2011 | 2 | 2023 | 151 | 0.100 |
Why?
| | Child | 4 | 2019 | 19129 | 0.100 |
Why?
| | Acute Lung Injury | 1 | 2014 | 310 | 0.100 |
Why?
| | Isoflurane | 1 | 2010 | 8 | 0.090 |
Why?
| | Anesthetics, Inhalation | 1 | 2010 | 14 | 0.090 |
Why?
| | Afghan Campaign 2001- | 2 | 2023 | 161 | 0.090 |
Why?
| | Disease Progression | 1 | 2017 | 2490 | 0.090 |
Why?
| | Genetic Vectors | 1 | 2011 | 302 | 0.090 |
Why?
| | Cell Movement | 1 | 2014 | 896 | 0.090 |
Why?
| | RNA, Messenger | 4 | 2018 | 2657 | 0.090 |
Why?
| | Cell Line | 5 | 2012 | 2707 | 0.090 |
Why?
| | Ischemic Attack, Transient | 1 | 2010 | 62 | 0.090 |
Why?
| | Neutrophils | 1 | 2015 | 1233 | 0.090 |
Why?
| | Motor Activity | 2 | 2011 | 660 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 2 | 2011 | 653 | 0.090 |
Why?
| | In Vitro Techniques | 1 | 2011 | 1094 | 0.090 |
Why?
| | Pregnancy | 3 | 2020 | 5691 | 0.080 |
Why?
| | Aged | 3 | 2022 | 19657 | 0.080 |
Why?
| | Oligodendroglia | 2 | 2023 | 152 | 0.080 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 814 | 0.080 |
Why?
| | Animals, Newborn | 2 | 2023 | 806 | 0.080 |
Why?
| | Kidney | 2 | 2012 | 1353 | 0.080 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2011 | 632 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2014 | 709 | 0.070 |
Why?
| | Menopause | 1 | 2010 | 266 | 0.070 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 124 | 0.070 |
Why?
| | Apoptosis | 3 | 2016 | 2484 | 0.070 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 26 | 0.070 |
Why?
| | B-Lymphocytes | 1 | 2011 | 770 | 0.070 |
Why?
| | Biomarkers | 1 | 2016 | 3588 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 1997 | 874 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2010 | 439 | 0.070 |
Why?
| | Cyclic Nucleotide-Gated Cation Channels | 1 | 2004 | 21 | 0.060 |
Why?
| | Hospital Mortality | 2 | 2021 | 814 | 0.060 |
Why?
| | Electrophysiology | 3 | 2003 | 204 | 0.060 |
Why?
| | Decorin | 1 | 2023 | 6 | 0.060 |
Why?
| | Infarction | 1 | 2023 | 16 | 0.060 |
Why?
| | Chondroitin Sulfates | 1 | 2023 | 35 | 0.060 |
Why?
| | Databases, Factual | 2 | 2021 | 1231 | 0.060 |
Why?
| | Cyclic AMP | 1 | 2004 | 242 | 0.060 |
Why?
| | Kv1.1 Potassium Channel | 1 | 2003 | 8 | 0.060 |
Why?
| | Genes, Lethal | 1 | 2003 | 25 | 0.060 |
Why?
| | Shal Potassium Channels | 1 | 2003 | 6 | 0.060 |
Why?
| | Acetazolamide | 1 | 2003 | 28 | 0.060 |
Why?
| | Carbonic Anhydrases | 1 | 2003 | 15 | 0.060 |
Why?
| | Rats, Wistar | 2 | 2017 | 399 | 0.060 |
Why?
| | Spatial Memory | 1 | 2022 | 16 | 0.060 |
Why?
| | Iraq | 1 | 2023 | 82 | 0.060 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 133 | 0.060 |
Why?
| | Afghanistan | 1 | 2023 | 108 | 0.050 |
Why?
| | Models, Neurological | 1 | 2004 | 216 | 0.050 |
Why?
| | Tolbutamide | 2 | 1999 | 7 | 0.050 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2021 | 8 | 0.050 |
Why?
| | Hypnotics and Sedatives | 1 | 2023 | 136 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2014 | 420 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 2 | 2011 | 44 | 0.050 |
Why?
| | Self Administration | 1 | 2021 | 125 | 0.050 |
Why?
| | Synaptic Transmission | 1 | 2003 | 239 | 0.050 |
Why?
| | Aorta, Thoracic | 2 | 2013 | 248 | 0.050 |
Why?
| | Adoptive Transfer | 2 | 2011 | 204 | 0.050 |
Why?
| | Ovariectomy | 2 | 2012 | 124 | 0.050 |
Why?
| | Tumor Necrosis Factors | 1 | 2020 | 9 | 0.050 |
Why?
| | Swine | 1 | 2023 | 730 | 0.050 |
Why?
| | Inflammation Mediators | 2 | 2013 | 502 | 0.050 |
Why?
| | Neurotoxins | 1 | 2020 | 27 | 0.050 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2001 | 192 | 0.050 |
Why?
| | Nucleus Accumbens | 1 | 2021 | 131 | 0.050 |
Why?
| | Coculture Techniques | 1 | 2020 | 208 | 0.040 |
Why?
| | Air Ambulances | 1 | 2020 | 32 | 0.040 |
Why?
| | Stress, Physiological | 1 | 2003 | 415 | 0.040 |
Why?
| | Up-Regulation | 1 | 2003 | 872 | 0.040 |
Why?
| | Dendritic Spines | 1 | 2020 | 52 | 0.040 |
Why?
| | Risk Assessment | 2 | 2021 | 3057 | 0.040 |
Why?
| | Thapsigargin | 1 | 1999 | 18 | 0.040 |
Why?
| | Cesium | 1 | 1999 | 17 | 0.040 |
Why?
| | Ion Transport | 1 | 1999 | 60 | 0.040 |
Why?
| | Lymph Nodes | 2 | 2011 | 455 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 975 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2003 | 1158 | 0.040 |
Why?
| | Glutamic Acid | 1 | 2020 | 224 | 0.040 |
Why?
| | Oligodendrocyte Precursor Cells | 1 | 2018 | 19 | 0.040 |
Why?
| | Barium | 1 | 1997 | 27 | 0.040 |
Why?
| | Calcium Signaling | 1 | 2019 | 219 | 0.040 |
Why?
| | Seizures | 1 | 2020 | 345 | 0.040 |
Why?
| | Thiourea | 1 | 1997 | 38 | 0.040 |
Why?
| | Aged, 80 and over | 2 | 2021 | 6561 | 0.040 |
Why?
| | Magnesium | 1 | 1997 | 150 | 0.040 |
Why?
| | Resuscitation | 1 | 2020 | 253 | 0.040 |
Why?
| | Exons | 1 | 2018 | 307 | 0.040 |
Why?
| | Hypoxia | 2 | 2014 | 963 | 0.040 |
Why?
| | Inpatients | 1 | 2021 | 388 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 1997 | 88 | 0.040 |
Why?
| | Adult | 2 | 2021 | 31512 | 0.040 |
Why?
| | Kinetics | 2 | 1997 | 1624 | 0.040 |
Why?
| | Niacinamide | 1 | 1997 | 70 | 0.040 |
Why?
| | Protein Domains | 1 | 2018 | 212 | 0.040 |
Why?
| | Oligopeptides | 1 | 1999 | 252 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2018 | 345 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2018 | 290 | 0.040 |
Why?
| | Protein Transport | 1 | 2018 | 412 | 0.040 |
Why?
| | Heme Oxygenase-1 | 1 | 2016 | 53 | 0.040 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2016 | 46 | 0.040 |
Why?
| | Adolescent | 3 | 2021 | 18480 | 0.040 |
Why?
| | Cell Polarity | 1 | 1997 | 133 | 0.040 |
Why?
| | Glucose Transporter Type 1 | 1 | 2016 | 42 | 0.040 |
Why?
| | Mice, Inbred ICR | 1 | 2016 | 111 | 0.040 |
Why?
| | Glutathione Transferase | 1 | 2016 | 97 | 0.040 |
Why?
| | Biological Transport | 1 | 2017 | 382 | 0.040 |
Why?
| | Stromal Cells | 1 | 2016 | 102 | 0.030 |
Why?
| | Cysteine | 1 | 1997 | 184 | 0.030 |
Why?
| | Cytokines | 2 | 2014 | 1900 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 732 | 0.030 |
Why?
| | Estrogen Receptor alpha | 2 | 2010 | 126 | 0.030 |
Why?
| | Functional Laterality | 1 | 2016 | 208 | 0.030 |
Why?
| | Receptors, Estrogen | 2 | 2012 | 387 | 0.030 |
Why?
| | T-Lymphocytes | 2 | 2015 | 1774 | 0.030 |
Why?
| | Adenosine Triphosphate | 1 | 1997 | 439 | 0.030 |
Why?
| | Pharmaceutical Preparations | 1 | 2017 | 167 | 0.030 |
Why?
| | Risk Factors | 2 | 2021 | 9000 | 0.030 |
Why?
| | Neurologic Examination | 1 | 2015 | 126 | 0.030 |
Why?
| | California | 1 | 2016 | 382 | 0.030 |
Why?
| | Nanostructures | 1 | 2016 | 100 | 0.030 |
Why?
| | Chronic Disease | 1 | 2021 | 1636 | 0.030 |
Why?
| | Blood Vessels | 1 | 2016 | 187 | 0.030 |
Why?
| | Hindlimb | 1 | 2015 | 137 | 0.030 |
Why?
| | Locomotion | 1 | 2015 | 83 | 0.030 |
Why?
| | Reactive Oxygen Species | 1 | 1997 | 576 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2014 | 180 | 0.030 |
Why?
| | Hematoxylin | 1 | 2013 | 2 | 0.030 |
Why?
| | Hypoglycemic Agents | 2 | 1999 | 1032 | 0.030 |
Why?
| | Eosine Yellowish-(YS) | 1 | 2013 | 6 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 1975 | 0.030 |
Why?
| | Arginine | 1 | 2015 | 249 | 0.030 |
Why?
| | Fluoresceins | 1 | 2013 | 47 | 0.030 |
Why?
| | Constriction | 1 | 2013 | 46 | 0.030 |
Why?
| | CREB-Binding Protein | 1 | 2013 | 28 | 0.030 |
Why?
| | Chalcones | 1 | 2013 | 9 | 0.030 |
Why?
| | Movement | 1 | 2016 | 248 | 0.030 |
Why?
| | Ligation | 1 | 2013 | 82 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2003 | 2445 | 0.030 |
Why?
| | Apamin | 2 | 2004 | 6 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 996 | 0.030 |
Why?
| | Mice, Inbred C3H | 1 | 2013 | 250 | 0.030 |
Why?
| | Fluorescein-5-isothiocyanate | 1 | 2012 | 38 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 226 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1474 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1868 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2001 | 1515 | 0.030 |
Why?
| | Fibronectins | 1 | 2012 | 114 | 0.030 |
Why?
| | Kidney Glomerulus | 1 | 2012 | 133 | 0.030 |
Why?
| | Lymphocyte Subsets | 1 | 2011 | 76 | 0.030 |
Why?
| | Proteins | 1 | 1997 | 938 | 0.030 |
Why?
| | Receptors, CCR7 | 1 | 2011 | 24 | 0.030 |
Why?
| | Comorbidity | 1 | 2016 | 1527 | 0.020 |
Why?
| | Receptors, CCR5 | 1 | 2011 | 54 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 1901 | 0.020 |
Why?
| | Hyaluronan Receptors | 1 | 2011 | 93 | 0.020 |
Why?
| | Mice, SCID | 1 | 2011 | 333 | 0.020 |
Why?
| | Blood | 1 | 2011 | 100 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2010 | 94 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2018 | 2275 | 0.020 |
Why?
| | Aromatase | 1 | 2010 | 31 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 403 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2012 | 316 | 0.020 |
Why?
| | Kidney Cortex | 1 | 2010 | 31 | 0.020 |
Why?
| | Aromatase Inhibitors | 1 | 2010 | 52 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2011 | 415 | 0.020 |
Why?
| | Blood Urea Nitrogen | 1 | 2010 | 59 | 0.020 |
Why?
| | Acute-Phase Proteins | 1 | 2010 | 67 | 0.020 |
Why?
| | Lipocalins | 1 | 2010 | 38 | 0.020 |
Why?
| | Lipocalin-2 | 1 | 2010 | 64 | 0.020 |
Why?
| | Renal Circulation | 1 | 2010 | 75 | 0.020 |
Why?
| | Oncogene Proteins | 1 | 2010 | 52 | 0.020 |
Why?
| | Estrogen Receptor beta | 1 | 2010 | 37 | 0.020 |
Why?
| | Exploratory Behavior | 1 | 2010 | 90 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 870 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2013 | 465 | 0.020 |
Why?
| | Castration | 1 | 2009 | 14 | 0.020 |
Why?
| | Blood Chemical Analysis | 1 | 2010 | 95 | 0.020 |
Why?
| | Androgen Receptor Antagonists | 1 | 2009 | 32 | 0.020 |
Why?
| | Androgen Antagonists | 1 | 2009 | 70 | 0.020 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2010 | 200 | 0.020 |
Why?
| | Middle Aged | 2 | 2021 | 27617 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4596 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2013 | 1171 | 0.020 |
Why?
| | Creatinine | 1 | 2010 | 491 | 0.020 |
Why?
| | Wound Healing | 1 | 2010 | 270 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2011 | 1085 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 693 | 0.020 |
Why?
| | Pediatrics | 1 | 2013 | 985 | 0.020 |
Why?
| | Autoimmunity | 1 | 2011 | 831 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 10793 | 0.020 |
Why?
| | Infant | 1 | 2018 | 8293 | 0.020 |
Why?
| | Child, Preschool | 1 | 2018 | 9491 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2004 | 311 | 0.010 |
Why?
| | Evoked Potentials | 1 | 2004 | 115 | 0.010 |
Why?
| | Intracellular Membranes | 1 | 2003 | 74 | 0.010 |
Why?
| | Blood Pressure | 1 | 2010 | 1664 | 0.010 |
Why?
| | COS Cells | 1 | 2003 | 184 | 0.010 |
Why?
| | Myoblasts | 1 | 2003 | 75 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2003 | 270 | 0.010 |
Why?
| | Muscle Denervation | 1 | 2001 | 9 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2003 | 152 | 0.010 |
Why?
| | Egtazic Acid | 1 | 2001 | 44 | 0.010 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2001 | 43 | 0.010 |
Why?
| | Cobalt | 1 | 2001 | 48 | 0.010 |
Why?
| | Chelating Agents | 1 | 2001 | 74 | 0.010 |
Why?
| | Potassium | 1 | 2001 | 132 | 0.010 |
Why?
| | Calcium Channels | 1 | 2001 | 150 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2159 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2003 | 2871 | 0.010 |
Why?
| | Biotransformation | 1 | 1997 | 52 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2003 | 1323 | 0.010 |
Why?
| | Potassium Channel Blockers | 1 | 1996 | 30 | 0.010 |
Why?
| | Leptin | 1 | 1997 | 231 | 0.010 |
Why?
| | Macromolecular Substances | 1 | 1996 | 201 | 0.010 |
Why?
| | Xenopus laevis | 1 | 1996 | 128 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1996 | 332 | 0.010 |
Why?
| | Oocytes | 1 | 1996 | 190 | 0.010 |
Why?
| | DNA Primers | 1 | 1996 | 533 | 0.010 |
Why?
|
|
Herson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|